Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of Directors
Senior management
Our history
Research and development
Technology platform
Therapeutic areas
Pipeline
Scientific papers and presentations
Partnering
Our approach
Our partnerships
Investors
Share information
Events & Presentations
Financial reports & Presentations
Financial calendar
Shareholder meetings
Shareholder information
Analyst coverage
Corporate governance
ESG
Newsroom
Press Releases
Image library
Glossary
Careers
Search
Research and development
Scientific papers and presentations
Sharing our discoveries and developments in our tireless pursuit of breakthrough therapies
Newest first
Oldest first
Posters & Papers
Presentations
Search
Reset
30/04/2026
Nykode Therapeutics Presents AI-Powered Immunotherapy Design Capabilities at BioPharma Drug Discovery Nexus 2026
20/04/2026
Immunogenicity of the therapeutic HPV16-specific cancer vaccine abipapogene suvaplasmid (VB10.16) in combination with pembrolizumab given as 1L treatment for HPV16+ PD-L1+ r/m oropharyngeal cancer: preliminary results from phase 1 of the VB-C-03 trial
27/03/2026
Development Of APC Targeted Antigen-Specific Immune Tolerance Therapies For Autoimmune Diseases
25/03/2026
VB10.NEO: The Journey of a Clinically ValidatedIndividualized Cancer Therapy from TumorBiopsy to Vaccine Administration
20/03/2026
ICHNO 2026 Presentation – Therapeutic Cancer vaccine abipapogene suvaplasmid (VB10.16) plus pembrolizumab as 1L treatment for HPV16-positive, PD-L1-positive r/m oropharyngeal cancer. A phase 1 dose-escalation trial
Pages:
1
2
3
4
5
6
7
8
9
10
11
12
13
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
